This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Chemed (CHE) Stock For Now
by Zacks Equity Research
Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.
Chemed (CHE) Roto-Rooter Sales Robust Despite COVID-19 Woes
by Zacks Equity Research
Chemed's (CHE) Roto-Rooter business gains from growing demand for plumbing, drain cleaning and excavation and water restoration services.
Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.
Chemed (CHE) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 3.75% and 0.61%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Chemed (CHE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ADUS or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.
Teleflex (TFX) Banks on Urolift Growth Amid Rising Expenses
by Zacks Equity Research
Despite reporting softer-than-expected revenues for the third quarter, Teleflex (TFX) notes that customer preference for UroLift continues to be driven by strong clinical results.
Henry Schein's (HSIC) New Deal Broadens Medical Supplies Arm
by Zacks Equity Research
The OMNIA Partners cooperative contract is expected to expand Henry Schein's (HSIC) offerings in the field of Point-of-Care testing, personal protective equipment and essential medical supplies.
Edwards (EW) States Long-Term Strategy, Provides 2022 View
by Zacks Equity Research
Edwards Lifesciences (EW) expects to reach significant milestones in 2022 including new product launches and progress in multiple significant clinical trials.
Thermo Fisher (TMO) Gets FDA PMA for Oncomine Dx Target Test
by Zacks Equity Research
Thermo Fisher's (TMO) Oncomine Dx Target Test will allow clinicians to use FFPE tissue samples to spot patients in the United States who may benefit from the important new therapy.
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong third-quarter performance and raised Roto-Rooter and earnings guidance for 2021.
Here's Why You Should Retain Baxter (BAX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.
HealthEquity (HQY) Q3 Earnings Beat, FY 2022 View Lowered
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust Interchange revenues in the third quarter of fiscal 2022.
Here's Why You Should Retain Tandem Diabetes (TNDM) for Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes (TNDM) on strong worldwide demand for Control-IQ technology and raised 2021 sales guidance.
CVS Health (CVS) New Alliance to Boost Digital Transformation
by Zacks Equity Research
CVS Health's (CVS) collaboration with Microsoft will accelerate digital transformation and empower employees to provide more customized and affordable care.
Here's Why You Should Retain Abiomed (ABMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.
BD's (BDX) Buyout of Venclose to Improve Patient Outcome
by Zacks Equity Research
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.
Thermo Fisher (TMO) Launches K-12 COVID-19 Test in Texas Schools
by Zacks Equity Research
Thermo Fisher's (TMO) ReadyCheckGo program will enable Texas schools to have the options for fast, reliable testing to identify and limit the spread of COVID-19 quickly.
Abbott (ABT) Nutrition Sales Strong Amid Spike in COVID Cases
by Zacks Equity Research
Abbott (ABT) is registering strong growth in its more consumer-facing businesses like nutrition, established pharmaceuticals and diabetes care.
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp
Quest Diagnostics (DGX) Expands Testing Suite With NGS Test
by Zacks Equity Research
Quest Diagnostics (DGX) offers Targeted Lung Panel Test at 2,200 conveniently located patient service centers across the United States.
4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic
by Riya Anand
Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.
DaVita (DVA) Study Favors mRNA Vaccines for Dialysis Patients
by Zacks Equity Research
DaVita's (DVA) latest study indicates favorable outcomes for ESKD patients regarding the COVID-19 vaccines.